Engineered extracellular vesicles based on membrane-cavity space separation strategy and their synergistic anti-tumor applications

By fusing LAMP2B-DNASE1L3 protein expressed on extracellular vesicles with miR-122-regulated IL-12 mRNA encapsulated in the lumen, a membrane-lumen space separation design was developed, solving the synergistic problem of DNASE1L3 and IL-12 delivery systems in existing technologies. This enabled precise enzymatic digestion and immune activation of the tumor microenvironment, significantly inhibiting tumor growth.

CN123107935APending Publication Date: 2026-11-17FOURTH MILITARY MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611516289.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-28
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies cannot achieve stable extracellular anchoring of DNASE1L3 within a single delivery system to precisely degrade the extracellular immunosuppressive barrier, while ensuring efficient intracavitary loading of IL-12 mRNA and tumor-specific controllable expression. This results in difficulty in synergistic barrier decomposition and immune activation, and the short half-life of the free enzyme and high toxicity of systemic administration of IL-12.

Method used

By fusing DNASE1L3 with LAMP2B, its catalytic domain is anchored to the outer side of the vesicle membrane, enabling in-situ enzymatic cleavage of the extracellular barrier. Simultaneously, IL-12 mRNA containing a miR-122 binding site is encapsulated within the vesicle lumen. The high expression of miR-122 in the liver enables organ-selective translational regulation of IL-12. The membrane-lumen spatial separation design ensures that the two do not interfere with each other physically and are sequentially advanced in function.

Benefits of technology

It achieved a systematic remodeling of the tumor immune microenvironment, promoted the infiltration of cytotoxic T cells and activation of immune responses, reduced the systemic toxicity of IL-12 and the risk of cytokine storm, significantly inhibited tumor growth and prolonged the survival of tumor-bearing mice.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107935A_ABST
    Figure CN123107935A_ABST
Patent Text Reader

Abstract

This invention discloses an engineered extracellular vesicle based on a membrane-cavity spatial separation strategy and its synergistic anti-tumor application, belonging to the field of biomedical technology. This invention fuses DNASE1L3 with LAMP2B for expression, anchoring its catalytic domain to the outer side of the vesicle membrane, precisely degrading tumor immunosuppressive extracellular matrix and promoting cytotoxic T lymphocyte infiltration; simultaneously, it loads a substance containing a miR-122 binding site within the vesicle cavity. Il12 This invention utilizes the low expression of miR-122 in the liver to inhibit the translation of IL-12 within the liver, achieving its specific expression in the tumor microenvironment, activating the anti-tumor immune response, and effectively avoiding systemic toxicity. The membrane-cavity separation design ensures that DNASE1L3 extracellular barrier clearance and IL-12 intracellular immune activation do not interfere with each other and synergistically enhance each other. Vesicles derived from dendritic cells naturally possess tumor homing ability. This invention addresses the bottlenecks of short half-life of free enzymes, high systemic toxicity of IL-12, and mutual constraints among carrier functional molecules, providing a safe and efficient new strategy for remodeling the immune microenvironment of solid tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, and more specifically to an engineered extracellular vesicle based on a membrane-cavity space separation strategy and its synergistic anti-tumor application. Background Technology

[0002] Immunotherapy for solid tumors such as colorectal cancer has long been limited by the immunosuppressive tumor microenvironment (TME), characterized by cytotoxic CD8. + Insufficient infiltration and impaired function of CTLs. In the tumor microenvironment, components such as immunosuppressive extracellular matrix and neutrophil extracellular trap-DNA can form a physical barrier, inhibiting CD8+. + The spatial distribution and cytotoxic function of T cells limit the efficacy of immune checkpoint blockade therapy. Recent studies have identified the deoxyribonuclease DNASE1L3, specifically expressed by tumor-infiltrating dendritic cells (DCs), as a way to promote CD8+ cytotoxicity by degrading the extracellular barrier. + T cell infiltration and function, and DNASE1L3 + The level of dendritic cell (DC) infiltration is positively correlated with a good prognosis in cancer patients treated with anti-PD-(L)1. DNASE1L3 has the ability to effectively clear tumor extracellular matrix and remodel the tumor immune microenvironment. However, free DNASE1L3 has a short half-life and lacks targeting, making it difficult to sustain its enzymatic barrier-breaking function in the tumor microenvironment.

[0003] Meanwhile, IL-12, as a substance that can enhance CD8 +IL-12 is a potent pro-inflammatory cytokine that kills T cells and can induce a sustained anti-tumor immune response. However, the systemic therapeutic window of IL-12 is extremely narrow, and existing literature (Zhang Y, Huang M, Zhang S, et al. Improving CAR-T cell function through a targeted cytokinedelivery system utilizing CAR target-modified extracellular vesicles. Exp Hematol Oncol. 2025;14(1):1. doi:10.1186 / s40164-025-00701.) shows that systemic administration of IL-12 easily induces severe inflammatory responses and systemic toxicity. In addition, extracellular vesicles, when used as drug delivery carriers, are partially enriched in the liver. When carrying IL-12 mRNA, they can lead to the translation and expression of IL-12 in the liver, thereby causing systemic toxicity and cytokine storms, which severely limits the clinical application of IL-12.

[0004] While existing technologies include engineered strategies for displaying exogenous proteins on the surface of extracellular vesicles using the LAMP2B transmembrane protein, and studies on delivering IL-12 mRNA via extracellular vesicles for tumor therapy, achieving both precise enzymatic degradation of the extracellular immunosuppressive barrier and controllable intratumoral expression of IL-12 within a single delivery system, and effectively disrupting the immunosuppressive barrier while safely activating anti-tumor immunity and reshaping the tumor immune microenvironment, remains a challenge for tumor immunotherapy using engineered extracellular vesicles. The extensive extracellular matrix deposits in the tumor immune microenvironment severely restrict the intratumoral infiltration of effector T cells. Simply relying on IL-12 to activate the immune response while neglecting barrier dissolution makes it difficult to achieve effective contact between lymphocytes and tumor cells; merely degrading the extracellular matrix without providing sustained immune activation signals also fails to establish long-lasting anti-tumor immunity. Furthermore, the short half-life and lack of targeting of free DNA SE1L3 limit its efficacy, while systemic administration of IL-12, due to its extremely narrow therapeutic window, easily induces hepatotoxicity and cytokine storms. Furthermore, when membrane-anchored enzymes and intraluminal mRNA are co-loaded in the same vesicle, the spatial localization, preparation compatibility, and action sequence of the two types of molecules can interfere with each other, and there is currently no systematic solution.

[0005] Therefore, how to achieve stable extracellular anchoring of DNASE1L3 within a single delivery system to precisely degrade the extracellular immunosuppressive barrier, while ensuring efficient intracavitary loading of IL-12 mRNA and achieving tumor-specific translation regulated by miR-122, so that the two do not interfere with each other spatially and synergistically enhance each other functionally, remains the core challenge currently facing tumor immunotherapy using engineered extracellular vesicles. Summary of the Invention

[0006] To address the technical problems of existing technologies being unable to simultaneously achieve stable extracellular membrane anchoring of DNASE1L3 to degrade the extracellular immunosuppressive barrier, efficient intracavitary encapsulation of IL-12 mRNA, and tumor-specific controllable expression within a single delivery system, resulting in difficulties in synergistic enzymatic barrier decomposition and immune activation, as well as the short half-life of free enzymes and high toxicity of systemic IL-12 administration, this invention provides an engineered extracellular vesicle based on a membrane-cavity spatial separation strategy and its synergistic anti-tumor application.

[0007] This invention utilizes the fusion expression of DNASE1L3 and LAMP2B to anchor its catalytic domain to the outer side of the vesicle membrane, achieving in-situ enzymatic cleavage of the extracellular barrier. Simultaneously, IL-12 mRNA containing a miR-122 binding site is encapsulated within the vesicle lumen, leveraging the high expression of miR-122 in the liver to achieve organ-selective translational regulation of IL-12. This membrane-lumen spatial separation design ensures that the two components do not interfere with each other physically and proceed sequentially in function, synergistically achieving a systemic remodeling of the tumor immune microenvironment.

[0008] To achieve the above objectives, the present invention employs the following technical solution: This invention provides an engineered extracellular vesicle, wherein the engineered extracellular vesicle is an extracellular vesicle derived from dendritic cells, comprising: Extracellular vesicle body; The fusion protein includes LAMP2B protein and DNASE1L3 protein, wherein the LAMP2B protein has a transmembrane domain and is anchored to the membrane of the extracellular vesicle body through its transmembrane domain, and the DNASE1L3 protein is fused with the LAMP2B protein and exposed on the outer side of the membrane of the extracellular vesicle body. In addition, an mRNA molecule loaded within the extracellular vesicle body cavity, the mRNA molecule encoding IL-12, and the 5'UTR region of the mRNA molecule having a miR-122 binding site.

[0009] Preferably, the fusion protein comprises, from N-terminus to C-terminus, a LAMP2B signal peptide, a LAMP2B transmembrane domain, a flexible linker peptide, and a DNASE1L3 protein; the DNASE1L3 protein is fused to the C-terminus of the LAMP2B protein via its N-terminus, and the enzymatic activity domain of the DNASE1L3 protein is exposed on the outer membrane of the extracellular vesicle body. This ensures that the catalytic domain of DNASE1L3 faces the extracellular space, enabling it to contact and degrade extracellular immunosuppressive components after the vesicle reaches the tumor microenvironment.

[0010] Preferably, the sequence of the miR-122 binding site is completely complementary to the nucleotide sequence of the mature miR-122. This ensures that miR-122 can efficiently recognize and bind to the 5'UTR region of IL-12 mRNA, thereby inhibiting IL-12 translation in hepatocytes.

[0011] Preferably, the 5'UTR region contains at least one miR-122 binding site. This ensures that IL-12 mRNA can be effectively recognized and bound by miR-122 in hepatocytes, thereby inhibiting its translation; at the same time, it ensures that IL-12 expression in the liver is effectively suppressed, while it can be efficiently translated and expressed in the tumor microenvironment, realizing a safe switch function of "silencing in the liver and activating in the tumor".

[0012] Preferably, the mRNA molecule contains, from the 5' end to the 3' end, a 5' cap structure, a 5' untranslated region, an IL-12 coding sequence, and a poly(A) tail, wherein the 5' untranslated region contains the miR-122 binding site. This ensures the stability and translation efficiency of the IL-12 mRNA in vivo.

[0013] Preferably, the DNASE1L3 protein exposed on the outer membrane of the extracellular vesicle body has enzymatic activity for degrading extracellular DNA. Preservation of this enzymatic activity is a prerequisite for achieving the degradation function of the extracellular immunosuppressive barrier. DNASE1L3, by degrading extracellular matrix components such as NET-DNA in the tumor microenvironment, opens the way for the infiltration of cytotoxic T cells, thereby reversing the immunosuppressive state.

[0014] Preferably, the extracellular vesicles derived from dendritic cells naturally express one or more of chemokine receptors, MHC class I molecules, MHC class II molecules, and co-stimulatory molecules. This endows the engineered extracellular vesicles with natural lymphatic homing ability and tumor tropism.

[0015] Preferably, the IL-12 is IL-12p70.

[0016] This invention provides a method for preparing the above-mentioned engineered extracellular vesicles, comprising the following steps: A fusion protein expression vector was constructed, which encodes the LAMP2B-DNASE1L3 fusion protein; The fusion protein expression vector was introduced into dendritic cells to obtain dendritic cells expressing the fusion protein; Dendritic cells expressing the fusion protein were cultured, the culture supernatant was collected, and the cells were separated and extracted to obtain extracellular vesicles with DNASE1L3 anchored on the outer membrane. Construct an mRNA molecule encoding IL-12, wherein the 5'UTR region of the mRNA molecule has a miR-122 binding site; The mRNA molecule is loaded into the cavity of the extracellular vesicle to obtain the engineered extracellular vesicle.

[0017] Preferably, the mRNA is loaded into the extracellular vesicles using electroporation.

[0018] This invention provides the application of the engineered extracellular vesicles in the preparation of antitumor drugs.

[0019] Preferably, the tumor is a solid tumor; more preferably, it is colorectal cancer.

[0020] Compared with the prior art, the present invention achieves the following technical effects: This invention provides an engineered extracellular vesicle comprising an extracellular vesicle body derived from dendritic cells, a LAMP2B-DNASE1L3 fusion protein exposed on the outer membrane, and IL-12 mRNA with a miR-122 binding site loaded within the lumen. This structure achieves a synergistic design of membrane-lumen spatial separation: the extracellular DNASE1L3 protein degrades immunosuppressive extracellular DNA and / or extracellular matrix in the tumor microenvironment, removing physical barriers to T cell infiltration; the intraluminal miR-122-regulated IL-12 mRNA translates and expresses IL-12 in the tumor microenvironment, activating an anti-tumor immune response. The two functional molecules are spatially isolated and do not interfere with each other, while functionally synergistically enhancing each other, solving the technical problem of mutual constraint between different functional molecules on the same carrier in existing technologies.

[0021] The preparation method provided by this invention achieves the engineered construction of a membrane-lumen spatially separated co-delivery structure by fusing DNASE1L3 with the transmembrane protein LAMP2B, inserting the miR-122 binding site into the 5'UTR of IL-12 mRNA, and first establishing dendritic cells stably expressing the fusion protein, collecting extracellular vesicles, and then electroporating to load the mRNA. This method is simple to operate, using dendritic cells as host cells. The extracellular vesicles secreted by these cells naturally highly express MHC I / II, co-stimulatory molecules, and chemokine receptors, and naturally possess lymphatic homing ability and tumor tropism. The engineered extracellular vesicles prepared achieve spatial separation between the extracellular anchoring of DNASE1L3 and the intraluminal loading of IL-12 mRNA, ensuring that the two do not interfere with each other and work synergistically.

[0022] The application provided by this invention utilizes engineered extracellular vesicles in the preparation of antitumor drugs. These engineered extracellular vesicles, through a membrane-cavity space-separated co-delivery design, achieve a synergistic therapeutic mechanism of immunosuppressive barrier clearance and intratumoral immune activation: the extracellular matrix and other immunosuppressive barriers are degraded by the DNASE1L3 enzyme on the outer membrane, promoting the infiltration of cytotoxic T cells; IL-12 mRNA within the cavity is translated and expressed in the tumor microenvironment, activating the immune response and promoting CD8+ expression. + T cell activation and proliferation work synergistically to reshape the tumor microenvironment from an immunosuppressive state to an immune-activated state, resulting in a synergistic anti-tumor therapeutic effect. Simultaneously, the miR-122 safety switch design reduces the systemic toxicity of IL-12 and the risk of cytokine storm. The engineered extracellular vesicles of this invention, through the synergistic effect of extracellular barrier degradation and intracavitary immune activation, can effectively reshape the tumor immune microenvironment, inhibit tumor growth, and prolong the survival of tumor-bearing mice, demonstrating promising applications in the preparation of anti-tumor drugs. Attached Figure Description

[0023] Figure 1 This is a schematic diagram of the engineered extracellular vesicle constructed in this invention, wherein: 1-engineered extracellular vesicle body; 2-DNASE1L3 protein anchored extracellularly; 3-LAMP2B protein; 4-IL-12 mRNA in the extracellular vesicle lumen; Figure 2 This is a schematic diagram of the transcript structure of IL-12 mRNA regulated by miR-122 in this invention; wherein: 5-promoter; 6-miR-122 recognition element; 7-IL12 coding sequence; Figure 3 This is a schematic diagram illustrating the particle size distribution analysis of extracellular vesicles in each group using the NTA method; where A represents control vesicles (EVs). Ctrl B represents DNASE1L3 membrane-anchored vesicles (EVs). DNASE1L3 C represents a vesicle (EV) co-carrying DNA SE1L3 and IL-12 mRNA. DNASE1L3+IL-12 ) Figure 4 This is a Western blot diagram showing the results of co-delivered extracellular vesicles constructed in this invention, compared with cell controls and other single-loaded vesicles (Ctrl group, EV). Ctrl Group, EV DNASE1L3 Group and EV DNASE1L3+IL-12 Group); Figure 5 This is a flow cytometry analysis of FITC-labeled blank control vesicles (EVs). Ctrl ) and engineered vesicles (EVs) DNASE1L3 FITC fluorescence signal quantitative quantification results of extracellular protein positive ratio; Figure 6This is for Western blotting to detect blank (PBS group) control vesicles (EVs). Ctrl Group) and engineered vesicles (EVs) DNASE1L3 Figure showing the expression levels of extracellular matrix markers in the group. Figure 7 The expression levels of IL-12 in normal mouse hepatocytes AML12 and tumor cells MC38 were detected by RT-qPCR in different treatment groups (Ctrl group, IL-12 group and miR-122 IL-12 group); Figure 8 Extracellular vesicles labeled with DiI were injected into the tail vein of mice (PBS group, EV group). Ctrl Group, EV DNASE1L3 Group and EV DNASE1L3+IL-12 Group 6 hours later, in vivo imaging results; Figure 9 This image shows the results of RT-qPCR detection of IL-12 expression in liver and tumor tissues of tumor-bearing mice after EVmiR-122 treatment (PBS group, EV group). IL-12 Group and EV miR-122 IL-12 Group); Figure 10 Different treatment groups (PBS group, EV group) Ctrl Group, EV DNASE1L3 Group, EV IL-12 Group, EV DNASE1L3+IL-12 Tumor growth curves (both physical and chemical combination groups); Figure 11 Different treatment groups (PBS group, EV group) Ctrl Group, EV DNASE1L3 Group, EV IL-12 Group, EV DNASE1L3+IL-12 Statistical graph of final tumor weight in subcutaneous tumor-bearing mice (group 1 and physical mixed group); Figure 12 After treating subcutaneous tumor-bearing mice with different vesicles (PBS group, EV group) Ctrl Group, EV DNASE1L3 Group, EV DNASE1L3+IL-12 CD8+ detection in various tumor tissues (both physical and chemical hybrid groups) by flow cytometry + A diagram illustrating the proportion of T cells. Detailed Implementation

[0024] To enable those skilled in the art to better understand the present invention, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings of the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort should fall within the scope of protection of the present invention.

[0025] For experiments not specifically described in the examples, the procedures or conditions should be followed according to the conventional experimental procedures described in the literature in this field. Reagents or instruments whose manufacturers are not specified are all commercially available conventional reagent products.

[0026] DNASE1L3: Deoxyribonuclease I-like protein 3, is a nuclease that can cleave extracellular DNA and chromatin and degrade immunosuppressive extracellular matrix in the tumor microenvironment.

[0027] LAMP2B: Lysosome-associated membrane protein 2B is a transmembrane protein enriched on the extracellular vesicle membrane and can be used to display exogenous proteins on the surface of EV membranes.

[0028] miR-122: microRNA-122 is a liver-specific microRNA that is abundant in hepatocytes but expressed at very low levels in other tissues.

[0029] Extracellular vesicles (EVs): Nanoscale vesicles secreted by cells with a lipid bilayer structure, typically 30-150 nm in diameter, carrying bioactive molecules such as proteins and nucleic acids, and playing an important role in intercellular communication.

[0030] IL-12: Interleukin-12 is a heterodimeric cytokine composed of p35 and p40 subunits that can promote CD8+ metabolism. + Activation and proliferation of T cells and NK cells enhance anti-tumor immune responses.

[0031] The 5' Untranslated Region (5'UTR) is a non-coding sequence upstream of the 5' coding region of messenger RNA (mRNA). It contains regulatory elements such as ribosome binding sites and participates in the regulation of translation initiation. In this invention, the miR-122 binding site is inserted into the 5'UTR region of IL-12 mRNA, located upstream of the IL-12 open reading frame, enabling miR-122 to exert an inhibitory effect during the translation initiation stage.

[0032] Membrane-Lumen Spatial Separation: This invention proposes a technical concept that refers to the targeted loading of different functional molecules into different spatial regions of extracellular vesicles, namely the outer membrane (DNASE1L3) and the vesicle lumen (IL-12 mRNA), so that the two do not interfere with each other spatially and synergistically enhance each other functionally. The DNASE1L3 on the outer membrane can enzymatically break down the extracellular immunosuppressive barrier without entering the cell, while the IL-12 mRNA in the lumen is protected from RNase degradation by a lipid bilayer membrane and, after entering the tumor microenvironment, translates and expresses IL-12.

[0033] The tumor microenvironment (TME) is the microenvironment surrounding tumor cells, comprising various components such as tumor cells, immune cells, blood vessels, and the extracellular matrix. An immunosuppressive tumor microenvironment is a major obstacle to immunotherapy for solid tumors, and its characteristics include CD8+. + Insufficient T cell infiltration, enrichment of immunosuppressive cells (such as Treg cells), and excessive deposition of extracellular matrix, etc.

[0034] In this invention, the degradation of the immunosuppressive barrier by extracellular DNASE1L3 promotes T cell infiltration, while the translation of intraluminal IL-12 mRNA to express IL-12 activates T cell function. These two processes occur sequentially in time and work synergistically in space to produce a synergistic anti-tumor effect.

[0035] The mouse dendritic cell line DC2.4 used in this invention was purchased from Cyagen Biosciences (China), catalog number: M3-1401. HEK293T (human embryonic kidney cell line) was purchased from Cyagen Biosciences (China), catalog number: H4-1401; CT26 (mouse colon cancer cell line), MC38 (mouse colon cancer cell line), AML12 (mouse normal hepatocyte cell line), and Hepa1-6 (mouse liver cancer cell line) were all purchased from Cyagen Biosciences (China).

[0036] The RPMI 1640 medium, DMEM medium (high glucose), fetal bovine serum (FBS), and ITS cell culture additives used in the embodiments of this invention were purchased from HyClone Laboratories.

[0037] The pLVX-IRES-Puro lentiviral expression vector used in this embodiment of the invention was purchased from Unibio (catalog number: VT1464); the psPAX2 packaging plasmid was purchased from NovoPro (catalog number: V010353); the pMD2.G envelope plasmid was purchased from NovoPro (catalog number: V010404); the pUC57 cloning vector was purchased from NovoPro (catalog number: V012363); and the pmiR-GLO dual-luciferase reporter vector was purchased from Unibio (catalog number: VT1439). Anti-TSG101 antibody (rabbit polyclonal antibody), anti-CD9 antibody (rabbit monoclonal antibody), anti-CD81 antibody (rabbit monoclonal antibody), anti-Calnexin antibody (rabbit polyclonal antibody), anti-DNASE1L3 antibody (rabbit polyclonal antibody), anti-Collagen I antibody (rabbit monoclonal antibody), anti-Fibronectin antibody (rabbit monoclonal antibody), and HRP-labeled goat anti-rabbit IgG secondary antibody were all purchased from Proteintech. The cell lines (DC2.4, HEK293T, CT26, MC38, AML12, Hepa1-6) and plasmids (pLVX-IRES-Puro, psPAX2, pMD2.G, pUC57, pmiR-GLO) involved in this invention are all commercially available. The fusion genes, mRNA transcription templates, and other nucleic acid molecules involved in this invention can be prepared using conventional molecular biology methods (PCR amplification, overlap extension PCR, restriction enzyme digestion and ligation, etc.) according to the sequence information and construction methods disclosed in the examples.

[0038] Example 1: Preparation of engineered dendritic cell-derived extracellular vesicles This embodiment provides a method for preparing engineered extracellular vesicles based on a membrane-cavity spatial separation strategy. The engineered extracellular vesicles are derived from dendritic cells, with the LAMP2B-DNASE1L3 fusion protein anchored on their outer membrane and the lumen loaded with miR-122-regulated IL-12 mRNA. The specific steps are as follows: (1) Cell culture Mouse dendritic cell line DC2.4 was cultured in RPMI 1640 medium (Gibco) containing 10% fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin (Gibco) at 37°C in a 5% CO2 incubator. Cells were passaged or transfected when they reached 80%–90% confluence.

[0039] (2) LAMP2B-DNASE1L3 fusion protein expression vector Based on the coding sequences of the mouse LAMP2B gene (GenBank accession number: NM_001289758) and the mouse DNASE1L3 gene (GenBank accession number: NM_001347457), a LAMP2B-DNASE1L3 fusion gene was designed. The fusion gene, from N-terminus to C-terminus, contains: the signal peptide sequence of LAMP2B (encoding the first 30 amino acids at the N-terminus of the LAMP2B protein), the transmembrane domain sequence of LAMP2B (encoding amino acids 31-90 of the LAMP2B protein), a flexible linker peptide (Gly-Gly-Gly-Gly-Ser, i.e., the GGGGS linker), and the full-length coding sequence of DNASE1L3 (excluding its own signal peptide). Thus, the DNASE1L3 protein fuses with the C-terminus of the LAMP2B protein via its N-terminus.

[0040] The above-mentioned fusion gene fragment was amplified using overlap extension PCR. Specifically, using mouse DC2.4 cell cDNA as a template, the LAMP2B fragment (upstream primer as shown in SEQ ID NO.2, downstream primer as shown in SEQ ID NO.3) and the DNASE1L3 fragment (upstream primer as shown in SEQ ID NO.4, downstream primer as shown in SEQ ID NO.5) were amplified separately. The two fragments were spliced ​​together to form the LAMP2B-DNASE1L3 fusion gene by overlap extension PCR. The fusion gene was double-digested with restriction endonucleases EcoRI and XhoI, and then ligated into the similarly digested lentiviral expression vector pLVX-IRES-Puro (purchased from Unibio, catalog number VT1464). The vector was transformed into E. coli DH5α competent cells, and positive clones were screened and sequenced for verification.

[0041] (3) Construction of miR-122-regulated IL-12 mRNA expression vector like Figure 2 As shown, the transcript of the miR-122-regulated IL-12 mRNA constructed in this invention contains, from the 5′ end to the 3′ end, the following components in sequence: promoter 5 (T7 promoter sequence), 5′ untranslated region (containing miR-122 recognition element 6), II12 coding sequence 7, and 3′ poly(A) tail.

[0042] Total RNA was extracted from mouse DC2.4 cells and cDNA was obtained by reverse transcription. Using the cDNA as a template, the coding sequences of mouse Il12a (NCBI Gene ID 16159) and Il12b (NCBI Gene ID 16160) were amplified by PCR. The coding sequences of Il12a and Il12b were linked together using a flexible linker peptide (GGGGS) to form a single-stranded IL-12 fusion gene (Il12a-GGGGS-Il12b), ensuring the formation of a biologically active single-stranded IL-12 fusion protein after translation.

[0043] A miR-122 binding site sequence (i.e., miR-122 recognition element 6) was introduced upstream of the 5′ untranslated region (5′UTR) of the IL-12 fusion gene. The nucleotide sequence of miR-122 recognition element 6 is 5′-CAAACACCATTGTCACACTCCA-3′, as shown in SEQ ID NO.6, which is inversely complementary to the mature mouse miR-122 sequence 5′-TGGAGTGTGACAATGGTGTTTG-3′, as shown in SEQ ID NO.7. The 5′UTR sequence containing miR-122 recognition element 6 was fused with the IL-12 coding sequence 7, and an T7 promoter sequence (5′-TAATACGACTCACTATAGGG-3′, as shown in SEQ ID NO.8) and an optimized human β-globin 5′UTR sequence were introduced upstream of it to enhance translation efficiency. The complete transcription template was cloned into the pUC57 vector (GenScript) and sequenced for verification.

[0044] Using an in vitro transcription kit (Thermo Fisher Scientific, catalog number AM1345), the linearized plasmid described above was used as a template to synthesize miR-122-regulated IL-12 mRNA with a 5′ cap and a 3′ poly(A) tail (hereinafter referred to as miR-122-IL-12 mRNA). After the DNA template was removed by DNase I digestion, the transcript was purified using an mRNA purification column (NEB). The integrity and concentration of the mRNA were determined by agarose gel electrophoresis and Nanodrop.

[0045]

[0046] (4) Establishment of stable transfected dendritic cell lines The pLVX-LAMP2B-DNASE1L3 lentiviral expression vector was co-transfected with the packaging plasmids pMD2.G and psPAX2 (Addgene) in a specific ratio into HEK293T cells to obtain recombinant lentivirus. The viral supernatant was collected, filtered through a 0.45 μm filter, and then used to infect DC2.4 cells. Forty-eight hours after infection, puromycin (2 μg / mL) was added for selection. Selection was continued for 14 days to obtain a stable DC2.4 cell line expressing the LAMP2B-DNASE1L3 fusion protein (hereinafter referred to as DC2.4-LD cells).

[0047] (5) Collection and purification of engineered extracellular vesicles DC2.4-LD cells were cultured in FBS-free RPMI 1640 medium (supplemented with 1% ITS cell culture additive, Corning) at 37°C in a 5% CO2 incubator for 48 hours. The cell culture supernatant was collected.

[0048] The collected supernatant was centrifuged in the following steps: centrifuged at 300×g for 10 minutes at 4°C to remove cells and cell debris; the supernatant was transferred and centrifuged at 2000×g for 20 minutes at 4°C to remove dead cells and large debris; the supernatant was transferred and centrifuged at 10000×g for 30 minutes at 4°C to remove microvesicles and organelle debris.

[0049] The supernatant was filtered through a 0.22 μm filter membrane, and extracellular vesicles were purified by ultracentrifugation: centrifugation was performed at 100,000 × g for 90 minutes at 4°C to precipitate the extracellular vesicles, and the supernatant was discarded; the precipitate was resuspended in PBS, and then centrifuged again at 100,000 × g for 90 minutes at 4°C for washing; the supernatant was discarded, and the precipitate was resuspended in an appropriate amount of PBS to obtain purified engineered extracellular vesicles (hereinafter referred to as LD-EVs). The obtained product was aliquoted and stored at -80°C for later use.

[0050] (6) Loading of miR-122-regulated IL-12 mRNA miR-122-IL-12 mRNA was loaded into LD-EVs using electroporation. Specifically: purified LD-EVs (approximately 1 × 10⁻⁶ mRNA) were loaded into LD-EVs. 11The particles (particles) and miR-122-IL-12 mRNA (20 μg) were mixed in electroporation buffer (0.1 mM EDTA, 1 mM MgCl2, 10 mM HEPES, pH 7.4) to a total volume of 200 μL. The mixture was added to a 4 mm electroporation cuvette and electroporated using a BTXEC M830 electroporator with the following parameters: voltage 400 V, capacitance 150 μF, resistance ∞, and pulse time 10 ms. After electroporation, the sample was incubated at 37 °C for 30 min to restore vesicle integrity. RNase A (1 μg / mL) was then added and incubated at 37 °C for 15 min to remove uncoated free mRNA. Finally, Exosome Spin Columns (Invitrogen) were used to remove residual RNase and free mRNA, yielding engineered extracellular vesicles (hereinafter referred to as LD-EVs@IL-12) that simultaneously anchor DNASE1L3 extracellularly and encapsulate miR-122-IL-12 mRNA intraluminally. Their structure is shown below. Figure 1 As shown: The outer membrane of the engineered extracellular vesicle body 1 is anchored to DNASE1L3 protein 2 via LAMP2B protein 3, and the vesicle lumen contains miR-122-regulated IL-12 mRNA 4.

[0051] As a control, the following vesicles were prepared using the same method: DC2.4 cell lysate (Ctrl) was used as a cell control; unmodified DC2.4 cell-derived EVs (EVs) Ctrl ); Extracellular anchored DNASE1L3 EVs (EVs) DNASE1L3 ); EVs that co-deliver DNASE1L3 and IL-12 mRNA (EVs) DNASE1L3+IL12 ).

[0052] Example 2: Structural characterization of engineered extracellular vesicles Based on Example 1, this embodiment characterizes the engineered extracellular vesicles prepared in Example 1 to prove that the obtained product is an extracellular vesicle and that the LAMP2B-DNASE1L3 fusion protein has been successfully anchored to the vesicle membrane.

[0053] (1) Grain size and morphological identification Take purified EV DNASE1L3+IL-12 EV DNASE1L3 EV IL-12 and EV Ctrl10 μL of each sample was diluted with PBS to the appropriate concentration. The particle size distribution and particle concentration of each vesicle sample were detected using a Particle Metrix (ZetaView) nanoparticle tracking analyzer. Simultaneously, 10 μL of each vesicle sample was dropped onto a copper mesh support, allowed to stand at room temperature for 2 minutes, excess liquid was blotted off with filter paper, negatively stained with 2% phosphotungstic acid for 2 minutes, and allowed to air dry before observing the vesicle morphology under a transmission electron microscope (TEM, Hitachi HT7800).

[0054] See Figure 3 All experimental groups of EVs exhibited typical cup-shaped or spherical morphology, with the main particle size peak located in the range of 80-150 nm and an average particle size of approximately 120 nm. There were no significant differences among the groups. This indicates that extracellular anchoring of DNA SE1L3 and intraluminal encapsulation of mRNA did not significantly affect the basic morphology and particle size of EVs.

[0055] (2) Identification of extracellular vesicle markers Each experimental group of EVs samples (approximately 20 μg of protein) was lysed in RIPA lysis buffer (containing protease inhibitors) on ice for 30 minutes, centrifuged at 12,000 × g for 15 minutes, and the supernatant was collected. Protein concentration was determined using a BCA protein quantification kit (Thermo Fisher). An equal volume of protein (15 μg) was subjected to SDS-PAGE electrophoresis, transferred to a PVDF membrane, blocked with 5% skim milk for 1 hour, and then incubated overnight at 4°C with anti-TSG101 antibody (Abcam, 1:1000), anti-CD9 antibody (Abcam, 1:1000), anti-CD81 antibody (Abcam, 1:1000), anti-Calnexin antibody (Abcam, 1:2000, as a negative control), and anti-DNASE1L3 antibody (Abcam, 1:500), respectively. After washing, HRP-labeled secondary antibody (1:5000) was added and incubated at room temperature for 1 hour, followed by ECL chemiluminescence imaging.

[0056] Western Blot results are as follows Figure 4 As shown, EV Ctrl EV DNASE1L3+IL-12 and EV DNASE1L3 All EV samples showed positive expression of TSG101 and CD9, while expression was weak in the cell control (Ctrl), consistent with the expression characteristics of extracellular vesicle markers. GM130 was highly expressed in the cell control (Ctrl) but almost not expressed in all three EV groups, indicating that the prepared EV samples were of high purity and not significantly contaminated by intracellular Golgi components. GAPDH, used as an internal control, was expressed in both the cell control and EV groups. Ctrl EV DNASE1L3 and EV DNASE1L3+IL12There was no significant difference in the expression levels of TSG101 and CD9 among the three groups, proving that membrane-anchored DNASE1L3 or intraluminal IL-12 mRNA did not disrupt the basic structure of EVs.

[0057] (3) Verification of extracellular localization of DNASE1L3 (flow cytometry) To verify that the DNASE1L3 protein is located on the outer side of the EV membrane, flow cytometry was used to detect the positive rate of DNASE1L3 on the outer membrane. EVs were collected... DNASE1L3 and EV CTRL 1×10 each 9 The particles were incubated with FITC-labeled anti-DNASE1L3 antibody (Abcam, 1:200) at 4 °C in the dark for 30 minutes. After washing, the FITC fluorescence signal was detected using flow cytometry (BD FACS Canto II) to quantify the positive proportion of extracellular proteins.

[0058] See results Figure 5 As shown, EV DNASE1L3 Extracellular DNA SE1L3 positivity rate reached 60.3%, while WT-EV Ctrl The group showed almost no positive signal. This result confirms that the DNASE1L3 fusion protein is effectively exposed on the outer side of the vesicle membrane and is rarely encapsulated within the lumen, achieving a membrane-lumen spatial separation design.

[0059] (4) Verification of DNASE1L3 enzyme activity (extracellular matrix degradation experiment) To verify whether DNASE1L3 anchored to the outer membrane of EVs retains its enzymatic activity for degrading the extracellular matrix, primary cancer-associated fibroblasts (CAFs) derived from tumor tissue were treated as follows: (1) PBS control group; (2) EVs Ctrl Group; (3) EV DNASE1L3 After incubation at 37°C for 48 hours, cells in each group were lysed and total protein was extracted. The expression levels of extracellular matrix markers collagen I (Coll) and fibronectin were detected by Western blotting.

[0060] See Western Blot results. Figure 6 As shown, EV DNASE1L3 The expression levels of Collagen I and Fibronectin proteins in the group were significantly downregulated compared with the PBS control group and EVCtrl, demonstrating that the extracellularly anchored DNASE1L3 retained its complete enzyme activity and could effectively degrade the immunosuppressive extracellular matrix.

[0061] Furthermore, to directly verify the degradation activity of extracellular DNA SE1L3 on extracellular DNA / NET-DNA, the degradation of extracellular DNA after LD-EVs treatment can be detected using PicoGreen quantitative PCR or agarose gel electrophoresis. Preferably, extracellular DNA derived from tumor cells or NET-DNA released from PMA-stimulated neutrophils is co-incubated with LD-EVs, and the degree of DNA fragmentation is detected. This experiment further supports the presence of extracellular DNA SE1L3 as an enzyme that degrades extracellular DNA.

[0062] (5) Detection of the encapsulation efficiency of miR-122-regulated IL-12 mRNA EVs were extracted using the Trizol method. DNASE1L3+IL12 and EV IL-12 The total RNA in the samples was analyzed, and the copy number of miR-122-IL-12 mRNA was detected by real-time quantitative PCR (RT-qPCR) using specific primers. Simultaneously, standard curves were constructed by serially diluting in vitro transcribed miR-122-IL-12 mRNA samples with known copy numbers, and the mRNA loading in each EV sample was calculated based on the standard curves.

[0063] The results show that EV DNASE1L3+IL12 The loading efficiency of miR-122-IL-12 mRNA is approximately 1 × 10 10 Each EV particle carries 2.5 × 10⁻⁶ particles. 6 One mRNA molecule, with EV IL-12 There was no significant difference between the groups (P>0.05), indicating that the expression of the LAMP2B-DNASE1L3 fusion protein did not affect the ability of EVs to encapsulate mRNA.

[0064] Example 3: Verification of miR-122's regulation of IL-12 translation (1) Construction of a dual-luciferase reporter gene system To verify the regulatory effect of miR-122 recognition element 6 on IL-12 mRNA translation, a dual-luciferase reporter gene vector was constructed. IL-12 5′UTR sequences containing miR-122 recognition element 6 (experimental group) or IL-12 5′UTR sequences without miR-122 recognition element 6 (control group) were cloned upstream of the firefly luciferase encoding gene in the pmiR-GLO dual-luciferase reporter vector (Promega). This vector also carries the Renida luciferase gene as an internal control.

[0065] (2) Cell transfection and luciferase activity detection Mouse hepatocellular carcinoma cells Hepa1-6 (highly expressing miR-122) and mouse colon cancer cells CT26 (lowly expressing miR-122) were seeded into 24-well plates (5×10⁻⁶ cells per well). 4 Cells were cultured overnight. The reporter vector (500 ng / well) was co-transfected into each well using Lipofectamine 3000 (ThermoFisher). Forty-eight hours after transfection, the activities of firefly luciferase and kidney luciferase in each well were measured using a dual-luciferase assay kit (Promega), and the relative luciferase activity (firefly / kidney ratio) was calculated.

[0066] The results showed that in Hepa1-6 cells, the relative luciferase activity of the experimental group (containing miR-122 recognition element 6) was significantly lower than that of the control group, indicating that miR-122 effectively inhibited the translation of reporter genes containing its binding site. However, in CT26 cells, there was no significant difference between the experimental and control groups (P>0.05). These results confirm that miR-122 recognition element 6 can specifically inhibit the translation of IL-12 mRNA in hepatocytes, achieving organ-selective expression regulation and thus reducing the systemic toxicity of IL-12.

[0067] (3) Verification of IL-12 expression at the cellular level To validate the translation specificity of miR-122-regulated IL-12 mRNA at the cellular level, miR-122-IL-12 mRNA was transfected into normal mouse hepatocytes AML12 and mouse colon cancer cells MC38, respectively. Forty-eight hours after transfection, total RNA was extracted, and the transcriptional level of IL-12 was detected by RT-qPCR.

[0068] See results Figure 7 As shown, in AML12 hepatocytes, the IL-12 expression level in the IL-12 group was significantly increased, while the IL-12 transcription level in the miR-122 IL-12 group was significantly inhibited, similar to that in the Ctrl group. However, in MC38 tumor cells, IL-12 expression in both the IL-12 group and the miR-122 IL-12 group was significantly increased, with no significant difference between the two groups. These results demonstrate that miR-122 can specifically silence IL-12 expression in hepatocytes while achieving efficient expression in tumor cells, thus functioning as a "silencing in the liver, activation in the tumor" safety switch.

[0069] Example 4: In vivo targeting and miR-122 regulation validation of engineered extracellular vesicles (1) DiI fluorescently labeled EVs Take purified EVD NASE1L3+IL-12 EVD NASE1L3 EVD IL-12and EV Ctrl 1×10 each 11 The particles were incubated with DiI fluorescent dye (Invitrogen, final concentration 5 μM) at 37 °C in the dark for 30 minutes. Free dye was removed using Exosome Spin Columns to obtain the DiI-labeled EVs for each group.

[0070] (2) Establishment of tumor-bearing mouse model Male BALB / c mice aged 6-8 weeks (purchased from the Animal Experiment Center of Air Force Medical University) were subcutaneously injected with CT26 mouse colon cancer cells (1×10⁻⁶) into the right back. 6 Each tumor cell was resuspended in 100 μL of PBS. Tumors were allowed to grow to approximately 100 mm². 3 Mice were randomly divided into 4 groups (n=5 per group): PBS group, EV group, etc. Ctrl Group, EV DNASE1L3 Group and EV DNASE1L3+IL-12 Group.

[0071] (3) Live imaging detection Mice in each group were injected via tail vein with DiI-labeled EVs (1×10⁻⁶). 10 Particles / animal, resuspended in 200 μL PBS. Six hours after injection, fluorescence imaging was performed using a small animal in vivo imaging system (IVIS Spectrum, PerkinElmer) (excitation wavelength 549 nm, emission wavelength 565 nm). Mice were euthanized after imaging, and tumor tissues and major organs (heart, liver, spleen, lung, and kidney) were isolated for in vitro fluorescence imaging, and the fluorescence intensity of each tissue was quantitatively analyzed.

[0072] In vivo imaging results as follows Figure 8 As shown, EV DNASE1L3+IL-12 The fluorescence signal intensity at the tumor site in the group was significantly higher than that in EV. DNASE1L3 Group, EV IL-12 Group and EV Ctrl This study demonstrated that engineered EVs derived from dendritic cells naturally possess tumor homing ability. In the liver, EVs... DNASE1L3+IL-12 The fluorescence signal of the group was significantly lower than that of EV. IL-12 The group suggests that miR-122 recognition element 6 reduces the nonspecific enrichment of EVs in the liver.

[0073] (4) Verification of IL-12 expression at the animal tissue level To demonstrate in vivo that miR-122-regulated IL-12 can achieve tumor-specific expression and inhibit liver expression, samples were obtained from EVs. IL-12 (IL-12 mRNA vesicles without miR-122 binding site) and EV miR-122 IL-12Tumor-bearing mice treated with IL-12 mRNA vesicles containing miR-122 binding sites were sacrificed 48 hours after the last administration. Liver and tumor tissues were isolated, total RNA was extracted, and the transcriptional level of IL-12 was detected by RT-qPCR.

[0074] The results are as follows Figure 9 As shown, EV IL-12 The IL-12 transcription level was significantly increased in the liver tissue of the EV group, while the EV group showed a significantly increased IL-12 transcription level. miR-122 IL-12 The transcriptional level of IL-12 in liver tissue was extremely low, similar to that in the PBS group; in tumor tissue, EV... IL-12 Group and EV miR-122 IL-12 IL-12 expression was significantly high in both groups, with no significant difference between the two groups. This result confirms in vivo that extracellular vesicles carrying miR-122-regulated IL-12 can achieve tumor-specific expression and inhibit liver expression.

[0075] Example 5: Evaluation of the synergistic in vivo antitumor effect of engineered extracellular vesicles (1) Establishment of subcutaneous tumor-bearing model and group treatment Male BALB / c mice aged 6-8 weeks were injected subcutaneously into the right back with CT26 cells (1×10⁻⁶). 6 (One per tumor). Wait until the tumor volume grows to approximately 60-80 mm. 3 At that time, the mice were randomly divided into the following 6 groups (8 mice in each group): PBS control group (200 μL PBS); EV Ctrl Group (1×10) 10 (particles / piece) EV DNASE1L3 Group (i.e., single-load DNASE1L3 group, 1×10) 10 (particles / piece) EV IL-12 Group (i.e., single-load IL-12 group, 1×10) 10 Particles / each, containing IL-12 mRNA); EV DNASE1L3 + EV IL-12 Physical hybrid group (i.e. EV) DNASE1L3 With EV IL-12 Physical mixed group, 1×10 10 (Particles / each, mixed and injected); EV DNASE1L3+IL-12 Group (i.e., a co-delivery EV group, 1×10) 10 Each particle (each containing a DNA SE1L3 gene) is simultaneously anchored extracellularly to DNA SE1L3 and encapsulated intraluminally with IL-12 mRNA containing a miR-122 binding site.

[0076] Mice in each group were injected with the corresponding preparation (200 μL / mouse) via the tail vein on days 0, 3, 6 and 9, for a total of 4 administrations.

[0077] (2) Tumor growth monitoring and tumor weight analysis Measure the tumor's long diameter (L) and short diameter (W) every two days using calipers, according to the formula V = 0.5 × L × W. 2 Calculate tumor volume and plot tumor growth curve. Figure 10 At the treatment endpoint (day 16), mice were sacrificed, tumor tissue was removed and weighed. Figure 11 ).

[0078] Tumor growth curve results show ( Figure 10 ): Total delivery of EVs (EVs) DNASE1L3+IL-12 The tumor volume in the group with single DNA SE1L3 was significantly smaller than that in the group with EV DNASE1L3 ), single-load IL-12 group (EV) IL-12 The co-delivery group and the physical combination group demonstrated that the tumor growth inhibition was significantly better in the co-delivery group than in all control groups. The treatment endpoint, tumor weight, showed (…). Figure 11 ): This invention co-delivery group (EV) DNASE1L3+IL-12 The tumor weight was significantly lower than that of the single-load group and the physical mixed group.

[0079] The above results demonstrate that the "membrane-cavity spatial separation" design, which integrates extracellular DNASE1L3 anchoring and intracellular loading of IL-12 mRNA into the same extracellular vesicle, produces a significantly superior antitumor effect compared to single-drug or simple physical mixing. The physical mixing group and the co-delivery group have the same drug composition, differing only in spatial structure, yet the co-delivery group showed significantly better results, proving that the membrane-cavity spatial separation structure of this invention itself brings an unexpected synergistic effect, rather than a simple summation of the functional components.

[0080] (3) Analysis of the immune microenvironment of tumor tissue On day 12 of treatment, three mice from each group were sacrificed, and tumor tissue was dissected. The tumor tissue was minced and digested with collagenase IV (1 mg / mL) and DNase I (100 μg / mL) at 37°C for 30 minutes to prepare a single-cell suspension. Tumor-infiltrating lymphocytes (TILs) were enriched by Percoll density gradient centrifugation.

[0081] CD8 in TILs was detected by flow cytometry. + T cell ratio, CD8 + Granzyme B in T cells + and IFN-γ + Cell percentage. Flow cytometry results are as follows: Figure 12 As shown, EV DNASE1L3+IL-12 CD8 in tumor tissue+ T cells account for CD3 + The proportion of T cells was significantly higher than that of EVs. DNASE1L Group, EV IL-12 Groups and physical mixtures. EV DNASE1L3+IL-12 Group CD8 + Granzyme B in T cells + and IFN-γ + The proportion of cells was also significantly higher than in other groups.

[0082] The above results demonstrate that the spatial separation design of this invention enables the DNASE1L3 protein 2 to clear the extracellular immunosuppressive barrier and the intraluminal IL-12 mRNA 4 to synergistically translate and express IL-12 within the tumor, effectively reshaping the tumor immune microenvironment and promoting its transition from an immunosuppressive to an immune-activated state. The co-delivery group significantly outperformed the physical mixing group, further proving that the membrane-cavity spatial separation structure achieves spatial isolation and functional synergy of the two functional molecules, rather than a simple superposition.

[0083] Example 6: Safety evaluation of engineered extracellular vesicles (1) Liver function index testing On day 12 of treatment, blood was collected from the orbital venous plexus of mice in each group (n=3), and serum was separated. The levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the serum were detected using a fully automated biochemical analyzer to assess liver function damage.

[0084] The results show that: EV DNASE1L3+IL-12 Serum ALT and AST levels in the EV group mice were not significantly different from those in the PBS control group. IL-12 The group (without miR-122 recognition element 6) showed significantly elevated ALT and AST levels, suggesting that non-specific expression of IL-12 mRNA without miR-122 regulation in the liver caused liver injury. This indicates that the introduction of miR-122 recognition element 6 effectively reduced the hepatotoxicity of IL-12.

[0085] (2) Serum cytokine detection The levels of IL-12, IFN-γ, TNF-α and IL-6 in the serum of mice in each group were detected using a multifactorial cytokine assay kit (LEGENDplex, Biolegend).

[0086] The results show that: EV DNASE1L3+IL-12 The serum IL-12 level in the EV group mice was slightly higher than that in the PBS control group, but the difference was not significant. IL-12Serum IL-12 levels were significantly elevated in the group. The levels of IFN-γ, TNF-α, and IL-6 showed similar trends across the groups. This indicates that miR-122 recognition element 6 acts as a safety switch, effectively inhibiting systemic IL-12 expression and reducing the risk of cytokine storm.

[0087] The above content is only for illustrating the technical concept of the present invention and should not be construed as limiting the scope of protection of the present invention. Any modifications made to the technical solution based on the technical concept proposed in this invention shall fall within the scope of protection of the claims of this invention.

Claims

1. An engineered extracellular vesicle, which is a dendritic cell-derived extracellular vesicle, characterized in that, include: Extracellular vesicle body; The fusion protein includes LAMP2B protein and DNASE1L3 protein, wherein the LAMP2B protein has a transmembrane domain and is anchored to the membrane of the extracellular vesicle body through its transmembrane domain, and the DNASE1L3 protein is fused with the LAMP2B protein and exposed on the outer side of the membrane of the extracellular vesicle body. In addition, an mRNA molecule loaded within the extracellular vesicle body cavity, the mRNA molecule encoding IL-12, and the 5'UTR region of the mRNA molecule having a miR-122 binding site.

2. The engineered extracellular vesicle of claim 1, wherein, The fusion protein comprises, from N-terminus to C-terminus, the following components in sequence: LAMP2B signal peptide, LAMP2B transmembrane domain, flexible linker peptide, and DNASE1L3 protein; the DNASE1L3 protein is fused to the C-terminus of the LAMP2B protein via its N-terminus, and the enzymatic activity domain of the DNASE1L3 protein is exposed on the outer membrane of the extracellular vesicle body.

3. The engineered extracellular vesicle of claim 1, wherein, The sequence of the miR-122 binding site is completely complementary to the nucleotide sequence of the mature miR-122.

4. The engineered extracellular vesicle of claim 1, wherein, The 5'UTR region contains at least one miR-122 binding site.

5. The engineered extracellular vesicle of claim 1, wherein, The mRNA molecule contains, from the 5' end to the 3' end, the following in sequence: a 5' cap structure, a 5' untranslated region, an IL-12 coding sequence, and a poly(A) tail, wherein the 5' untranslated region contains the miR-122 binding site.

6. The engineered extracellular vesicle of claim 1, wherein, The DNASE1L3 protein exposed on the outer membrane of the extracellular vesicle body has enzymatic activity for degrading extracellular DNA.

7. The engineered extracellular vesicle of claim 1, wherein, The extracellular vesicles derived from dendritic cells naturally express one or more of the following: chemokine receptors, MHC class I molecules, MHC class II molecules, and co-stimulatory molecules.

8. The method of producing the engineered extracellular vesicle of any one of claims 1-7, wherein, Includes the following steps: A fusion protein expression vector was constructed, which encodes the LAMP2B-DNASE1L3 fusion protein; The fusion protein expression vector was introduced into dendritic cells to obtain dendritic cells expressing the fusion protein; Dendritic cells expressing the fusion protein were cultured, the culture supernatant was collected, and the cells were separated and extracted to obtain extracellular vesicles with DNASE1L3 anchored on the outer membrane. Construct an mRNA molecule encoding IL-12, wherein the 5'UTR region of the mRNA molecule has a miR-122 binding site; The mRNA molecule is loaded into the cavity of the extracellular vesicle to obtain the engineered extracellular vesicle.

9. The production method according to claim 8, characterized by, The mRNA was loaded into the extracellular vesicles using electroporation.

10. The use of the engineered extracellular vesicles according to any one of claims 1-7 in the preparation of antitumor drugs.